Anuncio

SRExpert

Deja de saltar entre 6 herramientas de Kubernetes.

Monitoreo, alertas, seguridad, despliegues Helm y operaciones con IA en una sola plataforma.

Probar 30 días gratis

Empresa

OpenAI

2610documentos

83últimos 7 días

arXiv AI Papers

RecreationWorld: Scalable and Verifiable Environments for Hybrid Computer-Use Agents

Computer-use agents (CUAs) have advanced along two separate lines: graphical interaction and software development through code and the command line. Real digital work requires both, interleaved rather than stacked end to end. We study hybrid CUAs that autonomously decide when to explore an interface, implement software, and run and visually verify their artifacts. We introduce RecreationWorld, a five-platform framework built around recreation: given a running reference, an agent must discover its behavior and build a faithful implementation with no prescribed workflow. RecreationWorld provides reproducible environments on Ubuntu, macOS, Windows, Android, and Web, plus a unified harness with native GUI control and coding tools. The running reference serves as an oracle for hidden behavioral tests, providing execution-grounded rewards. We scale trajectory generation with high-quality open-source applications. Models trained on these trajectories improve across five out-of-distribution coding and hybrid computer-use benchmarks and more frequently verify their rendered outputs, providing evidence of transfer beyond recreation. For held-out evaluation, we introduce RecreationBench, comprising 250 diverse tasks across domains and platforms. Reference-grounded programmatic and visual assertions cover action-conditioned outcomes at multiple interaction depths; each is validated on the reference and by human reviewers before the suite is frozen for automatic scoring. GPT-6 Astra leads at 58.1% overall, but passes all programmatic tests on just 2.8% of tasks. Agents reproduce static interface structure more reliably than interactions and computed outputs, while generated applications remain smaller and more monolithic than their references. We release the benchmark, environments, and test suites.

en

Introducing Kimi K3 on Amazon Bedrock

Kimi K3 from Moonshot AI is now available on Amazon Bedrock, giving you a powerful new open-weight option for coding and knowledge work. It offers native vision, a 1-million-token context window, and explicit prompt caching to reduce latency and input costs.

en
arXiv AI Papers

AutoRecLab: Describe the Experiment, Get the Code!

Empirical evaluation is central to recommender-systems (RecSys) research, but turning experimental designs into executable code remains a manual and error-prone task. We present AutoRecLab, a Python-based autonomous RecSys lab that automates RecSys experiments from natural-language prompts. Given a research idea, AutoRecLab derives explicit experiment requirements, builds and validates a prototype, and iteratively expands it into the requested full experiment. The workflow combines retrieval-augmented generation (RAG) for documentation lookup, static type verification, and execution-steered tree search. In our demonstration, AutoRecLab autonomously implements an explicit-to-implicit feedback conversion study. In a baseline comparison across six algorithms and three datasets, 8 of 9 runs succeed at an average cost of approx- imately $1 per run with GPT-5.4-mini.

en
arXiv AI Papers

TrialAtlas: Multi-Agent Research Organization for Clinical Trial Design and Optimization

Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely on clinical development planning (CDP) and probability of technical and regulatory success assessment to anticipate development risks, yet these decisions remain labor-intensive and subjective, requiring experts across clinical science, statistics, regulatory affairs, and competitive intelligence to jointly acquire, synthesize, and reason over heterogeneous evidence. Here, we introduce TrialAtlas, a memory-augmented multi-agent research organization for CDP that mirrors this collaborative process by coordinating specialized agents for literature synthesis, competitive trial intelligence, regulatory precedent analysis, and integrated reasoning over trial design and development risk. TrialAtlas further learns from historical clinical trials and regulatory outcomes, including prior New Drug Applications (NDAs), to ground its decisions in accumulated development experience. To evaluate these capabilities in an authentic regulatory setting, we introduce TrialAtlasBench, constructed from 291 FDA Complete Response Letters and spanning three practical tasks: detecting trial design deficiencies, recommending actionable design improvements, and predicting technical and regulatory success. TrialAtlas achieves an F1 score of 50.0% for deficiency detection, outperforming the strongest baseline by 6.1 points, and reaches 85.3% balanced accuracy and 84.7% F1 for prediction of technical and regulatory success, improving over the best baselines by 6.7 points in balanced accuracy and 12.0 points in Cohen's kappa. In expert evaluation, 86.4% of TrialAtlas-generated concerns were judged valid, compared with 83.1% for OpenAI DeepResearch and 59.3% for Gemini DeepResearch.

en